Abstract
Objectives: To compare the therapeutic ratio of chlorofluorocarbon (CFC) and hydrofluoroalkane-134a (HFA) formulations of fluticasone propionate (FP).
Methods: We performed a randomized, placebo-controlled, crossover study comparing 6 weeks of treatment with FP using 500 μg/d and 1,000 μg/d formulations of CFC and HFA. The primary end points were provocative dose of methacholine causing a 20% fall in FEV1 (PD20) and overnight urinary cortisol/creatinine excretion.
Results: Eighteen patients with mild-to-moderate asthma and geometric mean (SEM) PD20 of 82.3 μg (19.2 μg) completed the study. All treatments significantly improved PD20 values and morning peak expiratory flow vs placebo, while 1,000 μg/d was significantly better than 500 μg/d for the CFC formulation of FP (CFC-FP) but not the HFA formulation of FP (HFA-FP). Only 1,000 μg/d of CFC-FP caused significant suppression of overnight urinary cortisol/creatinine compared to placebo. There were no differences between formulations at either dose.
Conclusions: The increased airway benefit with CFC-FP > 500 μg/d was offset by greater systemic effects. Although HFA-FP had fewer systemic effects than CFC-FP at 1,000 μg/d, there was no benefit to increasing HFA-FP to > 500 μg/d.
Methods: We performed a randomized, placebo-controlled, crossover study comparing 6 weeks of treatment with FP using 500 μg/d and 1,000 μg/d formulations of CFC and HFA. The primary end points were provocative dose of methacholine causing a 20% fall in FEV1 (PD20) and overnight urinary cortisol/creatinine excretion.
Results: Eighteen patients with mild-to-moderate asthma and geometric mean (SEM) PD20 of 82.3 μg (19.2 μg) completed the study. All treatments significantly improved PD20 values and morning peak expiratory flow vs placebo, while 1,000 μg/d was significantly better than 500 μg/d for the CFC formulation of FP (CFC-FP) but not the HFA formulation of FP (HFA-FP). Only 1,000 μg/d of CFC-FP caused significant suppression of overnight urinary cortisol/creatinine compared to placebo. There were no differences between formulations at either dose.
Conclusions: The increased airway benefit with CFC-FP > 500 μg/d was offset by greater systemic effects. Although HFA-FP had fewer systemic effects than CFC-FP at 1,000 μg/d, there was no benefit to increasing HFA-FP to > 500 μg/d.
| Original language | English |
|---|---|
| Pages (from-to) | 618-623 |
| Number of pages | 6 |
| Journal | Chest |
| Volume | 122 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Aug 2002 |